AAIC 2020: blood p-tau217 demonstrates high accuracy as a biomarker for Alzheimer’s

Written by Sharon Salt, Senior Editor

Multiple studies presented at the Alzheimer’s Association International Conference (AAIC; 27–31 July 2020) have reported on advancements made in a blood test for Alzheimer’s disease. In these newly reported results, researchers have focused on a specific form of tau known as p-tau217, which appears to be the most specific to Alzheimer’s and the earliest to show measurable changes. Blood p-tau217 as a highly accurate biomarker for Alzheimer’s By measuring levels of p-tau217, an international team of researchers has been able to identify a highly accurate blood-based biomarker for the detection of Alzheimer’s disease – a finding that has been validated...

To view this content, please register now for access

It's completely free